Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30718905 | 1.00 | BACE1 (0.53) | BACE1HDAC1HDAC2CCR1TLR2 | |
| SCHEMBL2273496 | 0.86 | BACE1 (0.52) | BACE1HDAC1HDAC2CCR1CYP2A6 | |
| SCHEMBL1641368 | 0.85 | BACE1 (0.50) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL2322461 | 0.82 | BACE1 (0.55) | BACE1HDAC1HDAC2CCR1TLR2 | |
| SCHEMBL1599686 | 0.81 | BACE1 (0.58) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL5050008 | 0.81 | BACE1 (0.53) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL14780983 | 0.81 | BACE1 (0.53) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL27779108 | 0.81 | BACE1 (0.53) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL1599323 | 0.81 | BACE1 (0.53) | BACE1HDAC1HDAC2TLR2CYP2A6 | |
| SCHEMBL27620530 | 0.79 | BACE1 (0.52) | BACE1HDAC1HDAC2CCR1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2024-08-01 | — | — | US | disclosed |
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20220220097-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-07-14 | — | — | US | disclosed |
| EP-3521286-B1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECH LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-11124501-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-09-21 | — | — | US | disclosed |
| EP-3521286-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | Cancer Research Technology Ltd. (GB) | 2019-08-07 | — | — | EP | disclosed |
| US-20190106413-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-11 | — | — | US | disclosed |
| US-20170037036-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| US-20160289216-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-06 | — | — | US | disclosed |
| EP-3052492-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | Cancer Research Technology Limited (GB) | 2016-08-10 | — | — | EP | disclosed |
| CN-105837503-A | Preparation method for 6-bromine quinoline | 蚌埠中实化学技术有限公司 | 2016-08-10 | — | — | CN | disclosed |
| WO-2015049535-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-09 | — | — | WO | disclosed |
| US-8993767-B2 | Multiphoton activable quinoline derivatives, their preparation and their uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8993767-B2 | Multiphoton activable quinoline derivatives, their preparation and their uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-03-31 | — | — | US | disclosed |
| EP-2523937-B1 | Multiphoton activable quinoline derivatives, their preparation and their uses | CENTRE NAT RECH SCIENT (FR) | 2015-03-11 | — | — | EP | disclosed |
| US-20130116281-A1 | Multiphoton Activable Quinoline Derivatives, Their Preparation and Their Uses | UNIVERSITÉ PARIS CITÉ (FR) | 2013-05-09 | — | — | US | disclosed |
| US-20130116281-A1 | Multiphoton Activable Quinoline Derivatives, Their Preparation and Their Uses | UNIVERSITÉ PARIS CITÉ (FR) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106413-A1 | INHIBITOR COMPOUNDS | HSF1, HSP90AB1, HSP90AA1 | BACE1 1693/4885HDAC1 51/4885HDAC2 137/4885 |
| US-20240254110-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | BACE1 2289/4885HDAC1 655/4885HDAC2 1001/4885 |
| US-20170037036-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I | HSF1, HSP90AB1, HSPB1 | BACE1 2449/4885HDAC1 455/4885HDAC2 1100/4885 |
| US-20160289216-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | BACE1 2355/4885HDAC1 430/4885HDAC2 1081/4885 |
| US-11787786-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1 | HSF1, HSP90AB1, HSPB1 | BACE1 2289/4885HDAC1 655/4885HDAC2 1001/4885 |
| US-20130116281-A1 | Multiphoton Activable Quinoline Derivatives, Their Preparation and Their Uses | NQO2, ACHE, NQO1 | BACE1 1792/4885HDAC1 2538/4885HDAC2 3630/4885 |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | BACE1 2266/4885HDAC1 1304/4885HDAC2 1829/4885 |
| US-20220220097-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | HSF1, HSP90AB1, HSPB1 | BACE1 2289/4885HDAC1 655/4885HDAC2 1001/4885 |
| US-11124501-B2 | Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I | HSF1, HSP90AB1, HSPB1 | BACE1 2449/4885HDAC1 455/4885HDAC2 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.